广西鹭港生物医药科技

Guangxi Lugang Biopharmaceutical Technology is a Chinese biotechnology company headquartered in Nanning, specializing in the research, development, and production of plasma-derived therapeutics. The company is a key participant in the China-ASEAN biopharmaceutical cooperation, operating a large-scale industrial park dedicated to blood product manufacturing. Its core portfolio includes essential treatments such as human albumin, intravenous immunoglobulins, and coagulation factors designed to treat conditions like hypoproteinemia and hemophilia. By integrating advanced plasma fractionation technologies with large-scale production facilities, the company aims to address the critical shortage of blood products in the regional market. Guangxi Lugang Biopharmaceutical Technology plays a vital role in the local life sciences ecosystem through its focus on high-standard GMP manufacturing and biopharmaceutical innovation.